The prevalence of deleterious PVs in BARD1 in the BC group (0.25%) was significantly higher than in population controls (0.09%); however, the frequency of PVs in the OC group (0.12%) was similar to that observed in controls. This evidence concerns the gene BARD1 and breast cancer.